D-Cycloserine in Neuropsychiatric Diseases: A Systematic Review
Open accessThe DOI matches its Crossref record; 79 of the 79 references it cites were found in a registry or an index.
Abstract
D-Cycloserine, known from tuberculosis therapy, has been widely introduced to neuropsychiatric studies, since its central active mechanism as a partial NMDA-agonist has been found. In this review, we evaluate its therapeutic potential in neuropsychological disorders and discuss its pitfalls in terms of dosing and application frequency as well as its safety in low-dose therapy. Therefore, we identified 91 clinical trials by performing a Medline search. We demonstrate in part preliminary but increasing evidence that D-cycloserine may be effective in various psychiatric diseases, including schizophrenia, anxiety disorders, addiction, eating disorders, major depression, and autism as well as in neurological diseases, including dementia, Alzheimer's disease, and spinocerebellar degeneration. D-Cycloserine in low-dose therapy is safe, but there is still a need for new drugs with higher specificity to the different N-methyl-D-aspartate-receptor subunits.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures

Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source doesn’t support the claim as written.
In the citing paper
“At low doses (<100 mg/day), DCS acts as a functional NMDA receptor antagonist, whereas relatively higher doses (>750 mg/day) accelerate glycine site NMDA receptor potentiation and produce DCS’s antidepressant and anxiolytic effects [168].”
From Pharmacotherapies Targeting GABA-Glutamate Neurotransmission for Treatment-Resistant Depression (2023) · cites this paper as [168]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Studies using transcranial direct current stimulation (tDCS) have shown that DCS modulates neuroplasticity through long-term potentiation via action on cortical NMDA receptors in humans [168,169].”
From Pharmacotherapies Targeting GABA-Glutamate Neurotransmission for Treatment-Resistant Depression (2023) · cites this paper as [168]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Goodman & Gilman's The Pharmacological Basis of Therapeutics
Brunton, L. L. (1985) · Cited by 7,321
Goodman and Gilman's the Pharmacological Basis of Therapeutics
Stigelman, W. H., & Pharm, D. (1986) · Military Medicine · doi:10.1093/milmed/151.1.386 · Cited by 6,782
Negative Symptoms in Schizophrenia: Definition and Reliability
Andreasen, N. C. (1982) · Archives of General Psychiatry · doi:10.1001/archpsyc.1982.04290070020005 · Cited by 2,247
Walker, D. L., Ressler, K. J., Lu, K.-T., & Davis, M. (2002) · The Journal of Neuroscience · doi:10.1523/jneurosci.22-06-02343.2002 · Cited by 815
Applying extinction research and theory to cue‐exposure addiction treatments
Conklin, C. A., & Tiffany, S. T. (2002) · Addiction · doi:10.1046/j.1360-0443.2002.00014.x · Cited by 701
Danysz, W., & Parsons, C. G. (1998) · Pharmacological Reviews · doi:10.1016/s0031-6997(24)01382-6 · Cited by 649
A meta-analysis of D-cycloserine and the facilitation of fear extinction and exposure therapy
Norberg, M. M., Krystal, J. H., & Tolin, D. F. (2008) · Biological Psychiatry · doi:10.1016/j.biopsych.2008.01.012 · Cited by 510 · cited 3×
“A huge meta-analysis (Norberg et al., 2008) of data from human and animal studies showed a significant, though moderate, positive effect of DCS on exposure therapy/ fear extinction.”
BackgroundInfluentialEffects of D-Cycloserine on Extinction: Translation From Preclinical to Clinical Work
Davis, M., Ressler, K., Rothbaum, B. O., & Richardson, R. (2006) · Biological Psychiatry · doi:10.1016/j.biopsych.2006.03.084 · Cited by 498 · cited 1×
“The mechanism of action of DCS might change or even reverse under conditions with great stress and might be due to different surrounding neurotransmitter concentrations (Hood et al., 1989; Watson et al., 1990; Sheinin et al., 2001; Davis et al., 2006).”
BackgroundGoff, D. C., Tsai, G., Levitt, J., Amico, E., Manoach, D., Schoenfeld, D. A., Hayden, D. L., McCarley, R., & Coyle, J. T. (1999) · Archives of General Psychiatry · doi:10.1001/archpsyc.56.1.21 · Cited by 436
Glycine binding primes NMDA receptor internalization
Nong, Y., Huang, Y.-Q., Ju, W., Kalia, L. V., Ahmadian, G., Wang, Y. T., & Salter, M. W. (2003) · Nature · doi:10.1038/nature01497 · Cited by 429
Cited by
Structure, Function, and Pharmacology of Glutamate Receptor Ion Channels
Hansen, K. B., Wollmuth, L. P., Bowie, D., Furukawa, H., Menniti, F. S., Sobolevsky, A. I., Swanson, G. T., Swanger, S. A., Greger, I. H., Nakagawa, T., et al. (2021) · Pharmacological Reviews · doi:10.1124/pharmrev.120.000131 · Cited by 686
Delost, M. D., Smith, D. T., Anderson, B. J., & Njardarson, J. T. (2018) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.8b00876 · Cited by 409
Pathophysiology and Current Drug Treatments for Post-Stroke Depression: A Review
Frank, D., Gruenbaum, B. F., Zlotnik, A. A., Semyonov, M., Frenkel, A., & Boyko, M. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms232315114 · Cited by 174
Glutamatergic synapses in neurodevelopmental disorders
Moretto, E., Murru, L., Martano, G., Sassone, J., & Passafaro, M. (2018) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2017.09.014 · Cited by 136
Al-shaibani, M. M., Mohamed, R. M. S. R., Sidik, N. M., Enshasy, H. A. E., Al-Gheethi, A. A. S., Noman, E. A., Al‐Mekhlafi, N. A., & Zin, N. M. (2021) · Molecules · doi:10.3390/molecules26154504 · Cited by 121
Huang, Q., Xie, Y., Hu, Z., & Tang, X. (2019) · Brain Research · doi:10.1016/j.brainres.2019.146549 · Cited by 117
Anti-NMDA Receptor Encephalitis: Clinical Features and Basic Mechanisms
Lynch, D. R., Rattelle, A., Dong, Y., Roslin, K., Gleichman, A. J., & Panzer, J. A. (2017) · Advances in pharmacology · doi:10.1016/bs.apha.2017.08.005 · Cited by 108
Novel drug developmental strategies for treatment‐resistant depression
Borbély, É., Simon, M., Fuchs, E., Wiborg, O., Czéh, B., & Helyes, Z. (2022) · British Journal of Pharmacology · doi:10.1111/bph.15753 · Cited by 106
Cheng, Y., Lin, C., & Lane, H. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22052283 · Cited by 92
The glycine site of NMDA receptors: A target for cognitive enhancement in psychiatric disorders
Peyrovian, B., Rosenblat, J. D., Pan, Z., Iacobucci, M., Brietzke, E. M., & McIntyre, R. S. (2019) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2019.02.001 · Cited by 82
Neuropsychiatric Effects of Antimicrobial Agents
Zareifopoulos, N., & Panayiotakopoulos, G. D. (2017) · Clinical Drug Investigation · doi:10.1007/s40261-017-0498-z · Cited by 79
Autoimmune Encephalitis: An Expanding Frontier of Neuroimmunology
Guan, H., Ren, H., & Cui, L. (2016) · Chinese Medical Journal · doi:10.4103/0366-6999.180514 · Cited by 70
Do specific NMDA receptor subunits act as gateways for addictive behaviors?
Hopf, F. W. (2016) · Genes Brain & Behavior · doi:10.1111/gbb.12348 · Cited by 68
Shin, W., Kim, K., Serraz, B., Cho, Y. S., Kim, D., Kang, M., Lee, E.-J., Lee, H., Bae, Y. C., Paoletti, P., et al. (2020) · PLOS Biology · doi:10.1371/journal.pbio.3000717 · Cited by 63
Autoimmune phenotypes in schizophrenia reveal novel treatment targets
Severance, E. G., Dickerson, F., & Yolken, R. H. (2018) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2018.05.005 · Cited by 58
Díaz-Caneja, C., State, M., Hagerman, R., Jacquemont, S., Marín, O., Bagni, C., Umbricht, D., Simonoff, E., de Andrés-Trelles, F., Kaale, A., et al. (2021) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2021.02.020 · Cited by 55
Cycloserine for treatment of multidrug-resistant tuberculosis: a retrospective cohort study in China
Li, Y., Wang, F., Wu, L., Zhu, M., He, G., Chen, X., Sun, F., Liu, Q., Wang, X., & Zhang, W. (2019) · Infection and Drug Resistance · doi:10.2147/idr.s195555 · Cited by 54
Biased modulators of NMDA receptors control channel opening and ion selectivity
Perszyk, R. E., Swanger, S. A., Shelley, C., Khatri, A., Fernández‐Cuervo, G., Epplin, M. P., Zhang, J., Le, P., Bülow, P., Garnier‐Amblard, E. C., et al. (2020) · Nature Chemical Biology · doi:10.1038/s41589-019-0449-5 · Cited by 53
Pharmacotherapies Targeting GABA-Glutamate Neurotransmission for Treatment-Resistant Depression
Vecera, C. M., C. Courtes, A., Jones, G., Soares, J. C., & Machado-Vieira, R. (2023) · Pharmaceuticals · doi:10.3390/ph16111572 · Cited by 48
“Studies using transcranial direct current stimulation (tDCS) have shown that DCS modulates neuroplasticity through long-term potentiation via action on cortical NMDA receptors in humans [168,169].”
BackgroundHypothesis‐driven investigations of diverse pharmacological targets in two mouse models of autism
Rhine, M. A., Parrott, J. M., Schultz, M. N., Kazdoba, T. M., & Crawley, J. N. (2019) · Autism Research · doi:10.1002/aur.2066 · Cited by 47
The Adverse Effects of Tuberculosis Treatment: A Comprehensive Literature Review
Mereškevičienė, R., & Danila, E. (2025) · Medicina · doi:10.3390/medicina61050911 · Cited by 46
Adverse effects of oral second-line antituberculosis drugs in children
Schaaf, H. S., Thee, S. A., van der Laan, L., Hesseling, A. C., & Garcia‐Prats, A. J. (2016) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2016.1216544 · Cited by 45
Wei, I.-H., Chen, K.-T., Tsai, M.-H., Wu, C.-H., Lane, H.-Y., & Huang, C.-C. (2017) · Journal of Agricultural and Food Chemistry · doi:10.1021/acs.jafc.7b04217 · Cited by 42
Bacq, A., Astori, S., Gebara, E., Tang, W., Silva, B. A., Sanchez-Mut, J. V., Grosse, J., de Suduiraut, I. G., Zanoletti, O., Maclachlan, C., et al. (2018) · Molecular Psychiatry · doi:10.1038/s41380-018-0132-3 · Cited by 35
Nowacki, J., Wingenfeld, K., Kaczmarczyk, M., Chae, W. R., Salchow, P., Abu-Tir, I., Piber, D., Hellmann‐Regen, J., & Otte, C. (2020) · Translational Psychiatry · doi:10.1038/s41398-020-0789-7 · Cited by 34
Smits, J. A. J., Pollack, M. H., Rosenfield, D., Otto, M. W., Dowd, S. M., Carpenter, J. K., Dutcher, C. D., Lewis, E. M., Witcraft, S. M., Papini, S., et al. (2020) · JAMA Network Open · doi:10.1001/jamanetworkopen.2020.6777 · Cited by 33
New Developments in the Treatment of Depression, OCD, and Schizophrenia
Kalin, N. H. (2025) · American Journal of Psychiatry · doi:10.1176/appi.ajp.20250014 · Cited by 30
Jessen, M., Frederiksen, K., Yi, F., Clausen, R. P., Hansen, K. B., Bräuner‐Osborne, H., Kilburn, P., & Damholt, A. B. (2017) · Molecular Pharmacology · doi:10.1124/mol.117.108944 · Cited by 28
Aschbacher, K., Hendershot, C. S., Tison, G. H., Hahn, J. A., Avram, R., Olgin, J. E., & Marcus, G. M. (2021) · npj Digital Medicine · doi:10.1038/s41746-021-00441-4 · Cited by 27
d-Cycloserine enhances the bidirectional range of NMDAR-dependent hippocampal synaptic plasticity
Vestring, S., Dorner, A., Scholliers, J., Ehrenberger, K., Kiss, A., Arenz, L., Theiß, A., Rossner, P., Frase, S., du Vinage, C., et al. (2024) · Translational Psychiatry · doi:10.1038/s41398-023-02725-7 · Cited by 26
A review on comparative mechanistic studies of antimicrobial peptides against archaea
Varnava, K. G., Ronimus, R. S., & Sarojini, V. (2017) · Biotechnology and Bioengineering · doi:10.1002/bit.26387 · Cited by 26
Sebih, F., Rousset, M., Bellahouel, S., Rolland, M., de Jesus Ferreira, M. C., Guiramand, J., Cohen-Solal, C., Barbanel, G., Cens, T., Abouazza, M., et al. (2017) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.7b00036 · Cited by 24
Lucido, M. J., & Dunlop, B. W. (2025) · Brain Sciences · doi:10.3390/brainsci15020161 · Cited by 24
Drug treatment of autism spectrum disorder and its comorbidities in children and adolescents
Santosh, P., & Singh, J. (2016) · BJPsych Advances · doi:10.1192/apt.bp.115.014597 · Cited by 24
New Pharmacologic Approaches to the Treatment of Bipolar Depression
Keramatian, K., Chakrabarty, T., DuBow, A., Saraf, G., & Yatham, L. N. (2023) · Drugs · doi:10.1007/s40265-023-01872-x · Cited by 22
Translating precision medicine for autism spectrum disorder: A pressing need
Pérez‐Cano, L., Azidane, S., Sabido-Vera, R., Sirci, F., Durham, L., & Güney, E. (2023) · Drug Discovery Today · doi:10.1016/j.drudis.2023.103486 · Cited by 22
Glutamatergic dysregulation in mood disorders: opportunities for the discovery of novel drug targets
Panek, M., Kawalec, P., Malinowska‐Lipień, I., Brzostek, T., & Pilc, A. (2020) · Expert Opinion on Therapeutic Targets · doi:10.1080/14728222.2020.1836160 · Cited by 17
DeMayo, M. M., Watson, M., Harris, A. D., & McGirr, A. (2025) · Journal of Affective Disorders · doi:10.1016/j.jad.2025.02.062 · Cited by 17
Yang, S., Xu, Y., Wang, Y., Ren, F., Li, S., Ding, W., Ma, Y., & Zhang, W. (2018) · Molecules · doi:10.3390/molecules23020324 · Cited by 17
Aye, S. Z., Ni, H., Sein, H. H., Mon, S. T., Zheng, Q., & Wong, Y. (2021) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd013457.pub2 · Cited by 16
Jiang, Q., He, X., Shui, Y., Lyu, X., Wang, L., Xu, L., Zhu, C. H., Zou, L., Zhou, X., Cheng, L., et al. (2021) · Microbial Pathogenesis · doi:10.1016/j.micpath.2021.105078 · Cited by 16
Donello, J. E., McIntyre, R. S., Pickel, D. B., & Stahl, S. M. (2025) · Pharmaceuticals · doi:10.3390/ph18020157 · Cited by 15
“Sarcosine is an orthosteric glycine site-dependent NMDAR agonist, and D-cycloserine is an orthosteric glycine site NMDAR partial agonist [64,65].”
Advancing past ketamine: emerging glutamatergic compounds for the treatment of depression
Freudenberg, F., Reif-Leonhard, C., & Reif, A. (2024) · European Archives of Psychiatry and Clinical Neuroscience · doi:10.1007/s00406-024-01875-z · Cited by 15
Synergistic psychedelic - NMDAR modulator treatment for neuropsychiatric disorders
Heresco‐Levy, U., & Lerer, B. (2023) · Molecular Psychiatry · doi:10.1038/s41380-023-02312-8 · Cited by 15
Chen, R., Capitão, L. P., Cowen, P. J., & Harmer, C. J. (2020) · Psychological Medicine · doi:10.1017/s0033291720001221 · Cited by 15
Dindo, M., Grottelli, S., Annunziato, G., Giardina, G., Pieroni, M., Pampalone, G., Faccini, A., Cutruzzolà, F., Laurino, P., Costantino, G., et al. (2019) · Biochemical Journal · doi:10.1042/bcj20190507 · Cited by 15
Adhikari, Y., Ma, C., Chai, Z., & Jin, X. (2023) · Neurobiology of Disease · doi:10.1016/j.nbd.2023.106233 · Cited by 14
Goetghebeur, P., Wesnes, K. A., & Targum, S. D. (2019) · Journal of Alzheimer s Disease · doi:10.3233/jad-181094 · Cited by 13
Zhao, F., Atxabal, U., Mariottini, S., Yi, F., Lotti, J. S., Rouzbeh, N., Liu, N., Bunch, L., Hansen, K. B., & Clausen, R. P. (2021) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.1c01810 · Cited by 13
Davis-Reyes, B. D., Campbell, V. M., Land, M. A., Chapman, H. L., Stafford, S. J., & Anastasio, N. C. (2019) · Biochemical Pharmacology · doi:10.1016/j.bcp.2019.07.007 · Cited by 12
Soares, L. A., Nascimento, L. M. M., Guimarães, F. S., Gazarini, L., & Bertoglio, L. J. (2024) · Psychopharmacology · doi:10.1007/s00213-024-06596-8 · Cited by 12
Bioinformatics Perspective of Drug Repurposing
Patel, B., Gelat, B., Soni, M. N., Rathaur, P., & Johar, K. (2023) · Current Bioinformatics · doi:10.2174/0115748936264692230921071504 · Cited by 11
Purushotham, S. S., Reddy, N. M. N., D’Souza, M. N., Choudhury, N. R., Ganguly, A., Gopalakrishna, N., Muddashetty, R. S., & Clement, J. P. (2022) · Experimental Brain Research · doi:10.1007/s00221-022-06448-x · Cited by 10
Pharmacological management of neurocognitive impairment in schizophrenia: A narrative review
Arsenault‐Mehta, K., Hochman‐Bérard, M., Johnson, A., Semenova, D., Nguyen, B., Willis, J. V., Mouravska, N., Joober, R., & Zhand, N. (2023) · Neuropsychopharmacology Reports · doi:10.1002/npr2.12382 · Cited by 10
Schnitzer, T. J., Torbey, S., Herrmann, K. M., Kaushal, G., Yeasted, R., & Apkarian, A. V. (2016) · Molecular Pain · doi:10.1177/1744806916678627 · Cited by 10
LeVine, S. M., & Tsau, S. (2022) · Frontiers in Pediatrics · doi:10.3389/fped.2021.807973 · Cited by 10
Improved synthetic route for the GluN2-specific NMDA receptor glycine site agonist AICP
Zhao, F., Rouzbeh, N., Hansen, K. B., & Clausen, R. P. (2020) · Tetrahedron Letters · doi:10.1016/j.tetlet.2020.151653 · Cited by 10
Wieren, A. V., Durrant, J. D., & Majumdar, S. (2023) · Drug Development Research · doi:10.1002/ddr.22068 · Cited by 10
Assembly of Bacterial Surface Glycopolymers as an Antibiotic Target
Cho, H. (2023) · The Journal of Microbiology · doi:10.1007/s12275-023-00032-w · Cited by 9
Nowacki, J., Wingenfeld, K., Kaczmarczyk, M., Chae, W. R., Salchow, P., Deuter, C. E., Piber, D., & Otte, C. (2021) · Journal of Psychopharmacology · doi:10.1177/02698811211009797 · Cited by 9
Deutsch, S. I., & Burket, J. A. (2022) · Medical Clinics of North America · doi:10.1016/j.mcna.2022.05.002 · Cited by 9
Diet, Microbiome, and Neuropsychiatric Disorders
Javitt, G. A., & Javitt, D. C. (2018) · Elsevier eBooks · doi:10.1016/b978-0-12-811440-7.00013-2 · Cited by 8
Jordan, W., Siegel, R., Kumar, R., & Javitt, J. C. (2023) · International Journal of Toxicology · doi:10.1177/10915818231176971 · Cited by 8
Drugs Used in Tuberculosis and Leprosy
Smith, M. L., Accinelli, A., Tejada, F. R., & Kharel, M. K. (2016) · Side effects of drugs annual · doi:10.1016/bs.seda.2016.08.015 · Cited by 8
Chen, Y., Xu, Y., Yang, S., Li, S., Ding, W., & Zhang, W. (2019) · MicrobiologyOpen · doi:10.1002/mbo3.819 · Cited by 8
Diminich, E. D., Dickerson, F., Bello, I., Cather, C., Kingdon, D., Rouhakhtar, P. R., Hart, K. L., Li, C., Troxel, A. B., & GOFF, D. C. (2020) · Schizophrenia Research · doi:10.1016/j.schres.2020.06.015 · Cited by 7
Evidence-Based and Novel Psychological Therapies for People with Anorexia Nervosa
Carr, A., Tchanturia, K., Dufour, E., Cowan, M., & Himmerich, H. (2020) · IntechOpen eBooks · doi:10.5772/intechopen.92680 · Cited by 7
Finnegan, S., Harrison, O. K., Booth, S., Dennis, A., Ezra, M., Harmer, C. J., Herigstad, M., Guillaume, B., Nichols, T. E., Rahman, N. M., et al. (2023) · ERJ Open Research · doi:10.1183/23120541.00479-2022 · Cited by 7
NMDAR dysfunction in autism spectrum disorders: Lessons learned from 10 years of study
Lee, S., Moon, H., & Kim, E. (2025) · Current Opinion in Neurobiology · doi:10.1016/j.conb.2025.103023 · Cited by 7
Kim, H. S., Jung, J., Han, K., Kim, H., & Jeon, H. J. (2025) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2025.1425637 · Cited by 7
Influence social and healthcare support on psychiatric adverse events in MDR-TB patient
Reviono, R., Harsini, H., Aphridasari, J., Nugroho, I. G. B. I., & Damayanti, K. E. (2018) · The Journal of Infection in Developing Countries · doi:10.3855/jidc.10352 · Cited by 7
Drug Repurposing and Lysosomal Storage Disorders: A Trick to Treat
Mele, B. H., Rossetti, F., Cubellis, M. V., Monticelli, M., & Andreotti, G. (2024) · Genes · doi:10.3390/genes15030290 · Cited by 7
A systematic review of the pharmacological modulation of autobiographical memory specificity
Cawley, E., Piazza, G. G., Das, R., & Kamboj, S. K. (2022) · Frontiers in Psychology · doi:10.3389/fpsyg.2022.1045217 · Cited by 6
Ahamed, S. K., Raut, S. B., James, F., Canales, J. J., Sohal, S. S., Caruso, V., & Johnson, L. R. (2025) · Neuroscience · doi:10.1016/j.neuroscience.2025.08.023 · Cited by 6
Chen, S., Yan, L., Zeng, J., Meng, W., Zhuang, J., Chen, F., Guo, Y., El‐Aty, A. M. A., Ju, X., & Yang, S. (2025) · International Immunopharmacology · doi:10.1016/j.intimp.2025.115209 · Cited by 6
A Nucleophilic Activity‐Based Probe Enables Profiling of PLP‐Dependent Enzymes
Brody, S. I., Buonomo, J. A., Orimoloye, M. O., Jia, Z., Sharma, S., Brown, C. D., Baughn, A. D., & Aldrich, C. C. (2023) · ChemBioChem · doi:10.1002/cbic.202200669 · Cited by 6
Boudrioua, A., Li, Y., Hartke, A., & Giraud, C. (2020) · FEMS Microbiology Letters · doi:10.1093/femsle/fnaa062 · Cited by 6
D-Cycloserine-Induced Seizure Activity in the Emergency Department: A Case Report
Kuhrau, S., Boykin, T., & Rech, M. A. (2022) · Journal of Pharmacy Practice · doi:10.1177/08971900221074955 · Cited by 6
Becker, R., Pederick, J. L., Dawes, E. G., Bruning, J. B., & Abell, A. D. (2023) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2023.117509 · Cited by 6
Novel approaches for drug development against chronic primary pain: A systematic review
Tékus, V., Borbély, É., Göebel, A., Baron, R., Hajna, Z., & Helyes, Z. (2025) · British Journal of Pharmacology · doi:10.1111/bph.70228 · Cited by 5
Teopiz, K. M., Lo, H. K. Y., Lakhani, M., Kwan, A. T. H., Lim, P. K., Zhang, M. C., Wong, S., Le, G. H., Swainson, J., Cao, B., et al. (2025) · CNS Spectrums · doi:10.1017/s1092852925100278 · Cited by 5
Makuc, D., Švab, Ž., Naumoska, K., Plavec, J., & Časar, Z. (2020) · Molecules · doi:10.3390/molecules25071684 · Cited by 5
New pharmacological approaches in the treatment of schizophrenia
Muszyński, J., Bienert, A., Elsorady, R. W. M., & Rybakowski, F. (2025) · Pharmacological Reports · doi:10.1007/s43440-025-00722-9 · Cited by 4
Case report on cycloserine serum levels after treatment with oral terizidone and oral cycloserine
Rose, L., Thompson, J., Berry, L., & Venkatesan, P. (2023) · Clinical Infection in Practice · doi:10.1016/j.clinpr.2023.100335 · Cited by 4
Synergistic behavioral and neuroplastic effects of psilocybin-NMDAR modulator administration
Tal, T. B., Pogodin, I., Botvinnik, A., Lifschytz, T., Heresco‐Levy, U., & Lerer, B. (2025) · Translational Psychiatry · doi:10.1038/s41398-025-03428-x · Cited by 4
Forouzanfar, F., Ahmadzadeh, A. M., Pourbagher‐Shahri, A. M., & Gorji, A. (2025) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2025.177690 · Cited by 4
Mirhashemi, E., Bachman, P., Krishnan, G. P., Asarnow, R. F., & Forsyth, J. K. (2025) · Schizophrenia Research · doi:10.1016/j.schres.2025.06.001 · Cited by 4
NMDAR Down-Regulation: Dual – Hit Molecular Target For COPD – Depression Comorbidity
Heresco‐Levy, U., Haviv, J., & Caine, Y. G. (2024) · Journal of Inflammation Research · doi:10.2147/jir.s487650 · Cited by 4
Drugs Used in Tuberculosis and Leprosy
Tejada, F. R., Walk, A. R., & Kharel, M. K. (2015) · Side effects of drugs annual · doi:10.1016/bs.seda.2015.06.009 · Cited by 4
Tsai, H.-A., Shih, T.-M., Tsai, T., Hu, J.-W., Lai, Y.-A., Hsiao, J.-F., & Tsai, G. E. (2024) · Beilstein Journal of Nanotechnology · doi:10.3762/bjnano.15.42 · Cited by 4
Cheng, J., Li, J., Zheng, R. H., Xu, K., Ma, X., Qiu, J., Zhang, R., & Cai, X. (2025) · Microbiology Spectrum · doi:10.1128/spectrum.01437-25 · Cited by 4
AMPK Activation by ENERGI Ameliorates Behavioral and Synaptic Deficits in a Mouse Model of Autism
Chu, M.-C., Wu, C.-C., Chung, Y.-J., Chang, C.-Y., Wu, H.-F., Tsai, S.-C., Peng, T.-N., Yang, T.-J., & Lin, H. (2025) · Molecular Neurobiology · doi:10.1007/s12035-025-05533-w · Cited by 3
Ganesh, P., Kweon, J., Tom, J., Kim, H., Varone, G., McGirr, A., & Brown, J. (2025) · Research Square · doi:10.21203/rs.3.rs-7980692/v1 · Cited by 3
Pyrkosch, L., Lautenbacher, L. M., Mumm, J., Plag, J., Fehm, L., Fydrich, T., & Ströhle, A. (2024) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2024.10.018 · Cited by 3
Tranquilizers/Anxiolytics: Definition, Indications, Contraindications, and Treatment
Kloiber, S. M., & Konstantinou, G. (2022) · Springer eBooks · doi:10.1007/978-3-030-62059-2_59 · Cited by 3
Psychopharmacology of Autism Spectrum Disorders
Mooney, L. N., Fosdick, C., & Erickson, C. A. (2019) · Cambridge University Press eBooks · doi:10.1017/9781108297769.008 · Cited by 3
Correlations between stereotypies in ASD and neurotransmitters: a systematic review
Ramos, F. I. O., Martins, K. G. T. F., Bachur, T. P. R., & Aragão, G. F. (2023) · Revista Neurociências · doi:10.34024/rnc.2023.v31.14121 · Cited by 3
D-cycloserine effects on COPD and depression in a murine experimental model
Heresco‐Levy, U., Haviv, J., Caine, Y. G., Bao, J., Huang, T., Shen, C.-C., & Bogot, N. (2025) · Frontiers in Pharmacology · doi:10.3389/fphar.2025.1554337 · Cited by 3
Okada, M., Okubo, R., Yamamoto, N., & Motomura, E. (2025) · British Journal of Pharmacology · doi:10.1111/bph.70262 · Cited by 3
Martinez, E. J., Wong, D. H., Patel, A. J., Vaz, R. J., Busby, R. W., Zahler, R., Schefer, D., Zhao, H., Xu, X., Liu, Z., et al. (2026) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5c02607 · Cited by 3
Metadata
- Authors
- Schade, S., & Paulus, W.
- Affiliations
- Universitätsmedizin Göttingen (DE)
- Corresponding author
- Schade, Sebastian
- Venue
- International Journal of Neuropsychopharmacology
- Publisher
- Oxford University Press (OUP)
- Published
- 2015-09-12
- Volume
- 19
- Issue
- 4
- Pages
- pyv102
- ISSN
- 1461-1457 (ISSN-L)
- 1469-5111
- PMC
- PMC4851259
- OpenAlex
- W2336203720
- Cited by
- 135
- References
- 79
- Citations by year
- 2026: 13 · 2025: 23 · 2024: 10 · 2023: 18 · 2022: 10 · 2021: 13 · 2020: 11 · 2019: 14 · 2018: 8 · 2017: 7 · 2016: 7 · 2015: 1
- FWCI
- 0.96
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- cc-by
- Locations
- The International Journal of Neuropsychopharmacology (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- GoeScholar The Publication Server of the Georg-August-Universität Göttingen (Georg-August-Universität Göttingen) (submittedVersion, cc-by)
- HighWire Press Open Archive (submittedVersion)
- GRO (submittedVersion, cc-by)
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
- Health Sciences › Medicine › Psychiatry and Mental health › Schizophrenia research and treatment
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neuroscience and Neuropharmacology Research
- Keywords
- D-cycloserine, NMDA receptor partial agonist, schizophrenia, anxiety disorders, addiction, eating disorders, major depressive disorder, autism spectrum disorder, dementia, Alzheimer's disease, spinocerebellar degeneration, dosing and administration, neuropsychiatric disorders
- MeSH terms
- Animals, Mental Disorders, Cycloserine, Humans, Nervous System Diseases, Psychotropic Drugs, Receptors, N-Methyl-D-Aspartate, Excitatory Amino Acid Agonists
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.